Fig. 8

Model for predicting risk in immunotherapy. A The progression-free survival (PFS) rates for low- and high-risk score subgroups in the TCGA cohort were contrasted. B A table depicts the distribution of the immunological categories (C1, C2, C3, and C4) among risk categories. C The distinction between participants with high ratings and those with low ratings in terms of the immune modulation’s recognized function. D The effects of immunotherapy in groups at two risks. E The variation in immune infiltration between scores with two risks. *P < 0.05, **P < 0.01, ***P < 0.001